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Abstract
Background: The use of herbal medicines during pregnancy is very high globally and previous studies have pointed
out possible associations with adverse pregnancy outcomes. Nevertheless, the safety of herbal medicines in pregnancy
is under-explored in low-income countries experiencing high maternal and neonatal complications. We investigated
the associations between self-reported use of Mwanamphepo (a group of herbal medicines commonly used to induce
or hasten labour) and adverse maternal and neonatal outcomes in rural Malawi.
Methods: We conducted a cross-sectional analysis of secondary household data relating to 8219 births that occurred
between 2005 and 2010 in Mchinji district, Malawi. The data were collected as part of a cluster-randomised controlled
trial (RCT) that evaluated community interventions designed to reduce maternal and neonatal mortality. Data were
gathered on maternity history, demographic characteristics, pregnancy outcomes and exposure to Mwanamphepo.
Associations between self-reported use of Mwanamphepo and maternal morbidity as well as neonatal death or
morbidity were examined using mixed-effects models, adjusted for relevant covariates. All analyses were also adjusted
for the clustered nature of the survey.
Results: Of the 8219 births, Mwanamphepo was used in 2113 pregnancies, representing an estimated
prevalence of 25.7%. The self-reported use of Mwanamphepo was significantly associated with increased
occurrence of maternal morbidity and neonatal death or morbidity. Specifically, the odds of maternal
morbidity were 28% higher among self-reported users than non-users of Mwanamphepo (AOR = 1.28; 95% CI = 1.09–1.50)
and the probabilities of neonatal death or morbidity were 22% higher (AOR =1.22; 95% CI = 1.06–1.40) among neonates
whose mother reportedly used Mwanamphepo than those who did not.
Conclusion: The use of Mwanamphepo was associated with adverse pregnancy outcomes in rural Malawi. Thus, herbal
medicines may not be safe in pregnancy. Where possible, pregnant women should be discouraged from using herbal
medicines of unconfirmed safety and those who report to have used should be closely monitored by health
professionals. The study was limited by the self-report of exposure and unavailability of data relating to some possible
confounders.
Keywords: Herbal medicines, Medicinal plants, Pregnant women, Labour, Pregnancy outcomes, Pregnancy complications,
Neonatal death, Neonatal morbidity
* Correspondence: c.zamawe@ucl.ac.uk
University College London, Faculty of Population Health Sciences, Institute
for Global Health, 30 Guildford Street, London WC1N 1EH, UK
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zamawe et al. BMC Complementary and Alternative Medicine  (2018) 18:166 
https://doi.org/10.1186/s12906-018-2203-z
Background
Herbal medicine is a healing approach based on the use of
plants or plant extracts [1, 2], and is one of the most com-
mon complementary and alternative therapies in pregnancy
around the world. Though methods vary, studies have
shown that up to 80% of pregnant women in Italy [3], 55%
in the UK [4], 40% in Palestine [5], 35% in Taiwan [6] and
50% in Zimbabwe [7] utilised herbal remedies between
2009 and 2015. The indications for herbal medicines differs
from place to place and can be clinical or non-clinical. The
frequently reported clinical indications for herbal medicine
use are nausea and vomiting, labour pain, induction of
labour, swollen feet and back pain [8–11]. On the other
hand, the non-clinical motives include poor access to health
facilities, cultural beliefs and practices associated with preg-
nancy, dissatisfaction with biomedical health systems and
the belief that herbal remedies are relatively safe and effect-
ive [12–14].
Although herbal medicines are considered compara-
tively safe by some pregnant women, this claim is not
based on evidence and may be incorrect for two reasons.
First, owing to lack of sufficient data on safety, the risk of
adverse effects associated with herbal medicine use during
pregnancy may be higher compared to conventional medi-
cines [15, 16]. Secondly, the safety of any drug, including
herbs, cannot be guaranteed in pregnancy because of the
possible teratogenic effects [3, 17, 18]. So far, there is no
agreement on the safety of herbal medicines among preg-
nant women in the literature [19, 20]. Some studies have
demonstrated that herbal medicines are safe during preg-
nancy [21–23], whereas others have shown that they con-
tain active substances that may be harmful to both the
woman and the foetus [24–26]. This raises many ques-
tions regarding the safety of herbal medicines during preg-
nancy that need to be addressed. Considering the high use
of herbal medicines during pregnancy [7, 27] and poor
maternal and neonatal outcomes [28, 29] in many low-
income countries, it is important to explore the possible
link between the two in such settings yet studies on herbal
medicine’s safety have been mostly restricted to high and
upper middle-income countries.
Malawi is one of the poorest countries in the world,
with a maternal mortality ratio (MMR) of 439 deaths
per 100,000 live births and a neonatal mortality rate
(NMR) of 27 deaths per 1000 births [30]. The preva-
lence of herbal medicine use is yet to be assessed in
the country; however, anecdotal evidence suggests
that utilisation during pregnancy is common [31, 32].
For instance, a study in a rural Mulanje district found
heavy reliance on plants for medicine and docu-
mented over 20 plant species that are frequently used
during pregnancy [31]. The possible relation between
the use of herbal medicines and adverse pregnancy
outcomes in Malawi was first noted four decades ago
after a maternal death survey discovered that a sig-
nificant number of cases were diagnosed with toxic
effects of herbs [33]. A few years later, Bullough and
Leary [34] conducted a follow-up animal study and
found that some of the herbal medicines that trad-
itional birth attendants (TBA) prescribed to pregnant
women had oxytocic properties. They argued that the
use of such medicines while under the care of un-
skilled birth attendants could be harmful to pregnant
women. This has been corroborated by a recent na-
tional maternal death review commissioned by the
Malawi Ministry of Health, which found that some of
the traditional medicines that women used during
pregnancy induced strong uterine contractions that
often result in maternal morbidity and death [35].
Mwanamphepo (cissus/vitaceae plants species) is a
local Malawian name used to describe a group of
herbal medicines that are commonly used by preg-
nant women to induce or hasten labour [31, 32]. It
is often mixed with porridge and taken orally by
pregnant women who are due for delivery. To date,
there are no published studies that have assessed as-
sociations between Mwanamphepo use and adverse
pregnancy outcomes. Given that Malawi did not
make sufficient progress towards reducing maternal
mortality in the last 15 years [29], it is critical to
understand if the use of herbal medicines is one of
the stumbling blocks. This could provide evidence
necessary for policies and interventions concerning
the use of herbal medicines and other alternative
therapies during pregnancy. To this end, this study
was undertaken to describe the prevalence of and
factors associated with Mwanamphepo use and
evaluate the associations between self-reported use
of Mwanamphepo and adverse maternal and neo-
natal outcomes in rural Malawi.
Methods
Study design and setting
We conducted a cross-sectional analysis of household
survey data that were collected between 2005 and 2010
as part of a Cluster-Randomised Controlled Trial (RCT)
intended to evaluate women’s groups and volunteer
counselling interventions in Mchinji District, Malawi.
The RCT, including the study interventions, is described
in detail elsewhere [36–38].
The source of data and population
During the RCT, Mchinji district was divided into 48
clusters of about equal-sized population and 12 of
these were controls [37]. All women of childbearing
age (WCBA) who fell pregnant in the 48 clusters
were interviewed at one-month and six-months after
childbirth by trained interviewers to retrospectively
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gather data about maternity history, care seeking
practices, including use of Mwanamphepo, and preg-
nancy outcomes [36]. In the present study, we only
included data collected one-month after delivery due
to substantial missing data and potential recall biases
in the follow-up (6 months) interviews. Moreover,
we only used data from the 12 control clusters to
minimise the possible effects of the RCT interven-
tions on herbal medicine use and pregnancy
outcomes.
Conceptual framework
To guide our analysis, we identified and mapped con-
ceptual determinants of both pregnancy outcomes and
the use of herbal medicines during pregnancy as shown
in Fig. 1. The theoretical framework has been adapted
from a World Health Organisation’s discussion paper
[39] and a 10-year review of literature by Stokoe [40],
which discuss the determinants of maternal mortality in
the developing world. It is also based on the works of
Stanifer et al. [41] in Tanzania, Laelago et al. [42] in
Ethiopia and Nyeko et al. [43] in Uganda about factors
associated with the use of herbal medicines in
pregnancy. The framework permits us to hypothesise the
relationship between herbal medicine use and pregnancy
outcomes in limited resource settings as well as explore
potential confounders that needs to be accounted for in
the analysis.
Variables and measurements
The self-reported use of Mwanamphepo is the exposure of
interest (independent variable) in this study and the out-
come measures (dependent variables) are self-reported ma-
ternal morbidity and neonatal death/morbidity. The
maternal morbidity variable combines the following out-
comes: caesarean section, assisted vaginal delivery, prema-
ture rupture of membrane, any postnatal morbidity and
any delivery problem. The neonatal death/morbidity vari-
able combines neonatal death, meconium-stained liquor,
low birth weight, preterm birth and any neonatal morbidity.
Covariates were included based on their theoretical rele-
vance to the topic [40, 41] and this was informed by the
conceptual framework (Fig. 1). The variables that were
identified and included in all adjusted analyses are: attend-
ance of antenatal clinic, attendance of postnatal clinic, place
of delivery, number of antenatal visits, timing of the first
Fig. 1 Hypothetical determinants of pregnancy outcomes and the use of herbal medicines among pregnant women. The relationship between
exposure to herbal medicines and pregnancy outcomes is not clearly understood, hence, the broken line
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antenatal visit (gestational age), age, marital status, tribe, oc-
cupation, wealth tertiles and religion. Wealth tertiles were
constructed through principal components analysis involv-
ing the following variables: type of floor, type of roofing,
owns land, source of water, employed a household worker,
persons per household room, electricity at home, and own-
ership of motorbike, oxcart, car, bicycle and radio.
Data management and analysis
As part of the data quality control in the original study,
births and deaths identified by enumerators were independ-
ently confirmed by an interviewer and a random sample of
the interviews were repeated by field supervisors. Com-
pleted questionnaires were checked in full for completeness
and consistency by a team of data checkers. Further reviews
were done in the databases after data entry to check for dis-
crepancies and missing data. Mistakes were addressed by
checking the questionnaires or consulting the interviewers
or call-backs to the field for verification.
In the present analysis, original variables were
recoded or combined to suit the purpose of this study
and checked for consistency, errors, missing data and
outliers. The level of missing data on all variables was
very low (< 5%), hence cases with missing values were
only excluded from the analyses that included them
(analysis by analysis basis - pairwise deletion) [44]. As
data were clustered at individual (e.g. some women
had more than one pregnancy) and trial cluster levels,
mixed-effects models and svyset (Stata command)
were used to adjust for clustering. The main analysis
involved comparing maternal and neonatal adverse
outcomes among users and non-users of Mwanam-
phepo through mixed-effects models. For each out-
come measure, crude and adjusted models were
specified and all analyses were performed using Stata/
SE 13.1 (StataCorp LP, Texas, USA). The significance
level of 5% and 95% confidence interval were used.
Ethics statement
The original RCT was granted ethical permission in
Malawi by the National Health Sciences Research
Committee (MED/4/36/I/167) and in the UK by
UCL Institute of Child Health and Great Ormond
Street Hospital [36]. In the original study, verbal in-
formed consent was obtained from each participant
and this procedure was duly approved by the ethics
committees. Verbal consent was considered as ap-
propriate due to a high level of illiteracy in the study
setting.
Results
A total of 8286 births were recorded in the 12 clus-
ters and data on Mwanamphepo use was obtained for
8219 births representing a response rate of 99.2%. Of
the 8219 births, Mwanamphepo was used in 2113
pregnancies, representing a prevalence of 25.7%
(Table 1).
Women who delivered with a traditional birth at-
tendant (AOR = 3.65; 95% CI = 2.94–4.54) and at
home or on the way to a health facility (AOR = 2.31;
95% CI = 1.87–2.83) were more likely to utilise Mwa-
namphepo than those who delivered in a health facil-
ity. The odds of Mwanamphepo use were 17% lower
among women in the highest wealth tertile than their
counterparts in the lowest (AOR = 0.83; 95% CI = 0.
69–0.99). Unsuccessful previous pregnancy (e.g. still-
birth, neonatal death) was associated with the use of
Mwanamphepo in the current pregnancy (AOR = 1.32;
95% CI = 1.12–1.54). Increasing age was significantly as-
sociated with decreased likelihoods of using Mwanam-
phepo (AOR = 0.96; 95% CI = 0.95–0.98). Characteristics
of the participants and other factors related to the utilisa-
tion of Mwanamphepo during pregnancy are provided in
Table 1.
The self-reported use of Mwanamphepo was significantly
associated with increased odds of both maternal morbidity
and neonatal death or morbidity. In particular, the odds of
maternal morbidity were 28% higher among users than
non-users of Mwanamphepo (AOR= 1.28; 95% CI = 1.09–
1.50). The odds of neonatal death or morbidity were 22%
higher among neonates whose mothers reportedly used
Mwanamphepo than those who did not (AOR =1.22; 95%
CI = 1.06–1.40). The strength of the relationship between
maternal morbidity and Mwanamphepo slightly increased
after adjusting for covariates whereas that of neonatal
death/morbidity and Mwanamphepo attenuated but
remained significant (Table 2).
Discussion
The self-reported use of Mwanamphepo was associ-
ated with adverse pregnancy outcomes in rural
Malawi. The users tended to experience more
pregnancy-related complications and the probabilities
of death/morbidity was higher for their neonates
compared to non-users. Thus, there is evidence to
suggest a hypothesis that the use of Mwanamphepo
during pregnancy is a risk factor for maternal and
neonatal complications. In the literature, there is
conflicting evidence regarding this proposition.
While some studies have shown that the use of
herbal medicines during pregnancy is associated with
adverse pregnancy outcomes [24, 25, 45, 46], others
did not find such evidence [19, 45, 47]. This discrep-
ancy could be due to variations in or lack of data on
types of herbal medicines used, dosages or length of
exposure, time of use (seasonality or stage of preg-
nancy) and study locations among others [48, 49].
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Table 1 Characteristics of participants and factors associated with utilisation of Mwanamphepo during pregnancy (Mixed-effects
model, adjusted for clustering)
Characteristics Total No herbal
remedies utilised
Utilised herbal
remedies
COR (95% CI)
p-value
aAOR (95% CI)
p-value
n % or m(SD) n % or m(SD) n % or m(SD)
8219 100% 6106 74.3% 2113 25.7%
Age (years) 7834 26.9 (6.7) 5823 27.3 (6.7) 2011 25.8 (6.7) 0.96 (0.95–0.97) < 0.001 0.96 (0.95–0.98) < 0.001
Highest level of education
None (Ref.) 2440 29.7% 1828 30.0% 611 28.9%
Primary 5313 64.7% 3899 63.9% 1414 67.0% 1.06 (0.92–1.23) 0.439 0.95 (0.80–1.14) 0.601
Secondary or higher 457 5.6% 370 6.1% 87 4.1% 0.68(0.50–0.93) 0.018 0.68 (0.47–0.99) 0.042
Marital status
Currently married (Ref) 6858 83.5% 5205 85.3% 1653 78.3%
Never married 1012 12.3% 646 10.6% 366 17.3% 1.80 (1.49–2.18) < 0.001 1.30 (0.93–1.82) 0.118
Formerly marriedb 343 4.2% 250 4.1% 93 4.4% 1.21 (0.82–1.53) 0.474 1.10 (0.76–1.58) 0.615
Main occupation
Farming (Ref) 6993 85.2% 5250 86.1% 1743 82.6%
Salaried employee 128 1.6% 100 1.6% 28 1.3% 0.68 (0.40–1.15) 0.150 0.98 (0.53–1.81) 0.942
Self employed 210 2.5% 178 2.9% 32 1.5% 0.57 (0.36–0.90) 0.016 0.75 (0.45–1.26) 0.281
Student/no work 878 10.7% 570 9.4% 308 14.6% 1.73 (1.42–2.11) < 0.001 1.25 (0.88–1.77) 0.216
Wealth tertiles
Lowest (Ref) 2753 34.1% 1967 32.6% 786 38.3%
Middle 2655 32.8% 1962 32.5% 693 33.7% 0.91 (0.77–1.06) 0.216 0.97 (0.81–1.16) 0.759
Highest 2673 33.1% 2099 34.8% 574 28.0% 0.68 (0.57–0.80) < 0.001 0.83 (0.69–0.99) 0.053
Religion
Christian (Ref) 7965 97.0% 5920 97.1% 2045 96.9%
Muslim and others 244 3.0% 179 2.9% 65 3.1% 0.78 (0.54–1.13) 0.185 1.07 (0.69–1.66) 0.768
Ethnicity
Chewa (Ref) 7886 96.1% 5867 96.2% 2019 95.7%
Ngoni 199 2.4% 135 2.2% 64 3.0% 1.11 (0.74–1.65) 0.615 0.98 (0.62–1.55) 0.925
Others 125 1.5% 97 1.6% 20 1.3% 0.82 (0.48–1.41) 0.476 0.76 (0.39–1.45) 0.403
Attended antenatal clinic (ANC)
No (Ref) 337 4.1 269 4.4% 68 3.2%
Yes 7869 95.9 5826 95.6% 2043 96.7% 0.83 (0.59–1.17) 0.286 1.50 (0.35–6.35) 0.582
Gestational age (month) at first ANC 7572 5.8 (1.3) 5617 5.8 (1.3) 1995 5.7 (1.2) 0.92 (0.92–1.03) 0.305 0.29 (0.90–1.03) 0.276
Unsuccessful last pregnancy
No (Ref) 6172 95.1% 4731 95.5% 1441 93.9%
Yes 319 4.9% 225 4.5% 94 6.1% 1.33 (1.13–1.54) 0.002 1.32 (1.12–1.54) 0.001
At least four ANC visits
No (Ref) 4982 65.8% 3609 66.1% 1274 65.2%
Yes 2586 34.2% 1905 33.9% 689 34.8% 0.97 (0.84–1.12) 0.687 0.97 (0.81–1.16) 0.731
Place of delivery
Hospital/health facility (Ref) 3662 46.2% 3004 51.1% 658 32.3%
Traditional birth attendants 2191 27.7% 1414 24.0% 777 38.1% 3.71 (3.07–4.47) < 0.001 3.65 (2.94–4.54) < 0.001
Home/on the way to facility 2068 26.1% 1465 24.9% 603 29.6% 2.13 (1.79–2.59) < 0.001 2.31 (1.87–2.83) < 0.001
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This underlines the need for rigorous assessment of
exposures in studies evaluating the safety of herbal
medicines.
The prevalence of self-reported use of Mwanamphepo
among pregnant women in Mchinji district was 25.7%. As
far as we know, this is the first study to estimate the preva-
lence of herbal medicine use in Malawi and thus it will
serve as a benchmark for future studies in the country. The
prevalence is however, considerably different from those
observed in many sub Saharan countries [7, 24, 42, 50].
For instance, studies in South Africa, Zimbabwe, Ethiopia
and Nigeria have all reported estimates greater than 50%
[7, 24, 42, 50]. There are two possible explanations for this
inconsistency. First, the use of herbal medicines is cultur-
ally determined [12, 43, 51]; hence, the lower prevalence
of use observed in the present study could be attributed to
the differences in cultural settings. Secondly, the focus of
this study was relatively narrow as it was particularly inter-
ested in the use of Mwanamphepo and for that reason
other herbal medicines used during pregnancy were pos-
sibly not reported. Notwithstanding the lack of agreement
with other studies, we strongly believe that our prevalence
estimate is more reliable and representative of the popula-
tion under study due to relatively large sample size and
coverage area.
Giving birth at home or with a TBA appears to be
related to the use of Mwanamphepo and this is not
surprising as TBAs are known for prescribing herbal
medicines [35, 52, 53]. We have found that an unsuc-
cessful previous pregnancy increased the possibility of
using Mwanamphepo. In sub Saharan Africa, women are
responsible for protecting the pregnancy from spiritual
harm and those who do not, may be blamed if the preg-
nancy fails [51, 54]. So, if a woman lost her previous preg-
nancy, it is reasonable to suggest that she would want to
take extra precautions by among others turning to herbal
medicines [55]. It has been noted that higher house-
hold wealth, secondary education and an increase in
maternal age were associated with decreased prob-
abilities that a pregnant woman would utilise Mwa-
namphepo. Generally, there is little to no consensus
on the link between demographic characteristics and
herbal medicine use in pregnancy as studies have re-
ported conflicting evidence [7, 42, 43, 56, 57]. On
maternal age, young women could be more worried
about the pregnancy than older women due to lack
of experience and this could motivate them to fully
obey traditional practices, including the use of herbal
medicines, but this is likely to change over time (or
with age).
The study had limitations and strengths worth ac-
knowledging. Since both exposure and outcomes data
were self-reported by the participants as well as collected
at the same time, recall and social desirability biases can-
not be ruled out. The data used in this study was col-
lected for a different purpose, as such the exposure of
Table 1 Characteristics of participants and factors associated with utilisation of Mwanamphepo during pregnancy (Mixed-effects
model, adjusted for clustering) (Continued)
Characteristics Total No herbal
remedies utilised
Utilised herbal
remedies
COR (95% CI)
p-value
aAOR (95% CI)
p-value
n % or m(SD) n % or m(SD) n % or m(SD)
Received postnatal care
No (Ref) 4144 58.4% 3024 57.9% 1120 59.7%
Yes 2953 41.6% 2198 42.9% 755 40.3% 0.87 (0.75–1.01) 0.064 1.18 (1.00–1.39) 0.059
COR Crude odds ratio, AOR Adjusted odds ratio, SD Standard deviation, M mean, CI confidence interval
aAdjusted for attendance of antenatal clinic, attendance of postnatal clinic, place of delivery, number of antenatal visits, timing of the first antenatal visit
(gestational age), age, marital status, tribe, occupation, wealth tertiles and religion
bIncludes widowed, divorced and separated
Table 2 Associations between exposure to Mwanamphepo during pregnancy and adverse pregnancy outcomes (Mixed-effects
model, adjusted for clustering)
Outcome measures Total n (%) Non-exposed n (%) Exposed n (%) COR (95% CI) p-value aAOR (95% CI) p-value
Maternal morbidity
No (Rc) 6100 (74.2%) 4665 (76.4%) 1435 (67.9%)
Yes 2119 (25.8%) 1441 (23.6%) 678 (32.1%) 1.21 (1.05–1.38) 0.006 1.28 (1.09–1.50) 0.002
Neonatal death or morbidity
No (Rc) 3538 (43.1%) 2795 (45.8%) 744 (35.2%)
Yes 4680 (56.9%) 3311 (54.2%) 1369 (64.8%) 1.30 (1.16–1.46) < 0.001 1.22 (1.06–1.40) 0.006
COR Crude odds ratio, AOR Adjusted odds ratio, CI Confidence interval, Rc Reference category
aAdjusted for attendance of antenatal clinic, attendance of postnatal clinic, place of delivery, number of antenatal visits, timing of the first antenatal visit
(gestational age), age, marital status, tribe, occupation, wealth tertiles and religion
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interest may not have been rigorously measured. For ex-
ample, the dosage of mwanamphepo and actual time of
exposure were not recorded. Data were collected on
Mwanamphepo only and because of this it was not pos-
sible to adjust for the impact of other herbal medicines
that may have been utilised. The data may also be out-
dated as the RCT started in 2005. The strength of the
study lies in its large sample size and extended field-
work, which suggest robust statistical significance.
Conclusion
Herbal medicines may not be safe during pregnancy. In
this study, we have established that the use of Mwanam-
phepo during pregnancy in rural Malawi was associated
with adverse pregnancy outcomes. Although we are un-
able to draw a causal-effect relationship due to the na-
ture of our study, this observation cannot be taken
lightly, especially in countries experiencing high mater-
nal and neonatal mortality as well as morbidity. We call
upon health professionals to familiarise themselves with
the herbal medicines commonly utilised by pregnant
women in their work settings and deliberately create a
conducive environment that could facilitate disclosure of
herbal medicine use during consultations. As a precau-
tion, those who admit having used herbal medicines
should be closely monitored. Where possible, pregnant
women should also be discouraged from using herbal
medicines of unverified safety. Although the current
study has gone some way towards enhancing our under-
standing of the safety of Mwanamphepo during preg-
nancy, further work needs to be undertaken to confirm
if the use of Mwanamphepo or other types of herbal
medicine is a risk factor for pregnancy complications.
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